Recombinant Human BMPR-IA/ALK-3 Protein

COA

级别和纯度:

≥95%(SDS-PAGE)
见COA

表达系统: HEK293
Accession #: P36894
蛋白标签: C-His
生物活性: Immobilized Human ACVR2B at 1 μg/mL (100 μL/well) can bind Human BMPRIA with a linear range of 0.5-62.5 ng/mL
内毒素水平: <0.1 EU/μg

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

货号 (SKU)	包装规格	是否现货
rp143319-10μg	10μg	现货
rp143319-50μg	50μg	现货
rp143319-100μg	100μg	现货
rp143319-1mg	1mg	期货

查看相关系列

点击查看蛋白信息: BMPR1A

Accession#: P36894 (1) ALK-3 (1) BMPRIA (1) CD292 (1) Gene ID: 657 (1)

Skip to the end of the images gallery

Skip to the beginning of the images gallery

基本描述

产品名称	Recombinant Human BMPR-IA/ALK-3 Protein
别名	骨成型蛋白受体1A(BMPR1A)重组蛋白
英文别名	Activin receptor-like kinase 3 \| ALK-3 \| BMP type-1A receptor \| BMPR-1A \| EC 2.7.11.30 \| Serine/threonine-protein kinase receptor R5 \| SKR5 \| ACVRLK310q23del \| ALK-3 \| ALK3EC 2.7.11.30 \| BMP type-1A receptor \| BMPR1A \| BMPR-1A \| BMPRIA \| BMPR-IA \| bone mo
规格或纯度	无动物源, 无载体, 生物活性, ActiBioPure™, 无叠氮钠, ≥95%(SDS-PAGE), 见COA
产品介绍	Purity ≥95% (SDS-PAGE) Endotoxin level ＜0.1 EU/μg Function On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for BMP2, BMP4, GDF5 and GDF6. Positively regulates chondrocyte differentiation through GDF5 interaction. Mediates induction of adipogenesis by GDF6.
生物活性	Immobilized Human ACVR2B at 1 μg/mL (100 μL/well) can bind Human BMPRIA with a linear range of 0.5-62.5 ng/mL
内毒素水平	<0.1 EU/μg
表达系统	HEK293
种属	人(Human)
氨基酸	24-152 aa
序列	QNLDSMLHGTGMKSDSDQKKSENGVTLAPEDTLPFLKCYCSGHCPDDAINNTCITNGHCFAIIEEDDQGETTLASGCMKYEGSDFQCKDSPKAQLRRTIECCRTNLCNQYLQPTLPPVVIGPFFDGSIRHHHHHH
纯度	≥95% (SDS-PAGE)
蛋白标签	C-His
无载体	Yes
无动物源	Yes
Accession #	P36894
来源	重组表达
预测分子量	15 kDa
SDS-PAGE	28-33 kDa, under reducing conditions

储存与运输

物理形态	冻干(Lyophilized)
储存缓冲液	Lyophilized from 10mM PBS, 5% Trehalose, 5% Mannitol, pH 7.4
浓度	见COA
复溶	Reconstitute in sterile water to a concentration of 0.1-0.5 mg/ml.
储存温度	-20°C储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	长期储存-80℃（1年）；收货后建议分装，避免反复冻融。
分子类型	蛋白质

图片

SDS-PAGE: Recombinant Human BMPR-IA/ALK-3 Protein (rp143319)

Recombinant Human BMPR-IA/ALK-3 Protein (rp143319) - SDS-PAGE
2 μg/lane of Recombinant Human BMPR-IA/ALK-3 Protein was resolved with SDS-PAGE under reducing (R) and non-reducing (N) conditions and visualized by Coomassie® Blue staining, showing the band at 25 - 28 kDa under reducing conditions and 25 - 28 & 40 - 50 kDa under non-reducing conditions.

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到3个结果

批号(Lot Number)	证书类型	货号
ZJ25F0724217	分析证书	rp143319
ZJ25F0724216	分析证书	rp143319
ZJ25F0724215	分析证书	rp143319

引用文献

1. Weber D, Kotzsch A, Nickel J, Harth S, Seher A, Mueller U, Sebald W, Mueller TD. (2007) A silent H-bond can be mutationally activated for high-affinity interaction of BMP-2 and activin type IIB receptor.. BMC Struct Biol, 7 (6). [PMID:17295905]
2. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C et al.. (2007) Patterns of somatic mutation in human cancer genomes.. Nature, 446 (7132): (153-8). [PMID:17344846]
3. Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, Karaman MW, Pratz KW, Pallares G, Chao Q et al.. (2009) AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).. Blood, 114 (14): (2984-92). [PMID:19654408]
4. Engers DW, Frist AY, Lindsley CW, Hong CC, Hopkins CR. (2013) Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe.. Bioorg Med Chem Lett, 23 (11): (3248-52). [PMID:23639540]
5. Lafleur K, Huang D, Zhou T, Caflisch A, Nevado C. (2009) Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).. J Med Chem, 52 (20): (6433-46). [PMID:19788238]
6. Mohedas AH, Wang Y, Sanvitale CE, Canning P, Choi S, Xing X, Bullock AN, Cuny GD, Yu PB. (2014) Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.. J Med Chem, 57 (19): (7900-15). [PMID:25101911]
7. Feng Y, Yin Y, Weiser A, Griffin E, Cameron MD, Lin L, Ruiz C, Schürer SC, Inoue T, Rao PV, Schröter T, Lograsso P.. (2008) Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors.. J Med Chem, 51 (21): (6642-6645). [PMID:18834107] [10.1021/jm800986w]
8. Qiao L, Choi S, Case A, Gainer TG, Seyb K, Glicksman MA, Lo DC, Stein RL, Cuny GD.. (2009) Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors.. Bioorg Med Chem Lett, 19 (21): (6122-6126). [PMID:19783434] [10.1016/j.bmcl.2009.09.010]
9. Deng X, Lim SM, Zhang J, Gray NS.. (2010) Broad spectrum alkynyl inhibitors of T315I Bcr-Abl.. Bioorg Med Chem Lett, 20 (14): (4196-4200). [PMID:20541934] [10.1016/j.bmcl.2010.05.043]
10. Cuny GD, Ulyanova NP, Patnaik D, Liu JF, Lin X, Auerbach K, Ray SS, Xian J, Glicksman MA, Stein RL, Higgins JM.. (2012) Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors.. Bioorg Med Chem Lett, 22 (5): (2015-2019). [PMID:22335895] [10.1016/j.bmcl.2012.01.028]
11. Sunose M, Bell K, Ellard K, Bergamini G, Neubauer G, Werner T, Ramsden N.. (2012) Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.. Bioorg Med Chem Lett, 22 (14): (4613-4618). [PMID:22726925] [10.1016/j.bmcl.2012.05.090]
12. Reith AD, Bamborough P, Jandu K, Andreotti D, Mensah L, Dossang P, Choi HG, Deng X, Zhang J, Alessi DR, Gray NS.. (2012) GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor.. Bioorg Med Chem Lett, 22 (17): (5625-5629). [PMID:22863203] [10.1016/j.bmcl.2012.06.104]
13. Bowers S, Truong AP, Ye M, Aubele DL, Sealy JM, Neitz RJ, Hom RK, Chan W, Dappen MS, Galemmo RA, Konradi AW, Sham HL, Zhu YL, Beroza P, Tonn G, Zhang H, Hoffman J, Motter R, Fauss D, Tanaka P, Bova MP, Ren Z, Tam D, Ruslim L, Baker J, Pandya D, Diep L, Fitzgerald K, Artis DR, Anderson JP, Bergeron M.. (2013) Design and synthesis of highly selective, orally active Polo-like kinase-2 (Plk-2) inhibitors.. Bioorg Med Chem Lett, 23 (9): (2743-2749). [PMID:23522834] [10.1016/j.bmcl.2013.02.065]
14. Charnley AK, Convery MA, Lakdawala Shah A, Jones E, Hardwicke P, Bridges A, Ouellette M, Totoritis R, Schwartz B, King BW, Wisnoski DD, Kang J, Eidam PM, Votta BJ, Gough PJ, Marquis RW, Bertin J, Casillas L.. (2015) Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity.. Bioorg Med Chem, 23 (21): (7000-7006). [PMID:26455654] [10.1016/j.bmc.2015.09.038]
15. Klaeger S, Heinzlmeir S and Wilhelm M et al. (2017) The target landscape of clinical kinase drugs.. Science, 358 (6367): [PMID:29191878] [10.1126/science.aan4368]
16. Wang Q, Liu F, Qi S, Qi Z, Yan XE, Wang B, Wang A, Wang W, Chen C, Liu X, Jiang Z, Hu Z, Wang L, Wang W, Ren T, Zhang S, Yun CH, Liu Q, Liu J.. (2018) Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.. Eur J Med Chem, 150 (366-384). [PMID:29544149] [10.1016/j.ejmech.2018.03.003]
17. Hudson L, Mui J, Vázquez S, Carvalho DM, Williams E, Jones C, Bullock AN, Hoelder S.. (2018) Novel Quinazolinone Inhibitors of ALK2 Flip between Alternate Binding Modes: Structure-Activity Relationship, Structural Characterization, Kinase Profiling, and Cellular Proof of Concept.. J Med Chem, 61 (16): (7261-7272). [PMID:30085668] [10.1021/acs.jmedchem.8b00782]
18. Jiang JK, Huang X, Shamim K, Patel PR, Lee A, Wang AQ, Nguyen K, Tawa G, Cuny GD, Yu PB, Zheng W, Xu X, Sanderson P, Huang W.. (2018) Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.. Bioorg Med Chem Lett, 28 (20): (3356-3362). [PMID:30227946] [10.1016/j.bmcl.2018.09.006]
19. Wang B, Wu J, Wu Y, Chen C, Zou F, Wang A, Wu H, Hu Z, Jiang Z, Liu Q, Wang W, Zhang Y, Liu F, Zhao M, Hu J, Huang T, Ge J, Wang L, Ren T, Wang Y, Liu J, Liu Q.. (2018) Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.. Eur J Med Chem, 158 (896-916). [PMID:30253346] [10.1016/j.ejmech.2018.09.025]
20. Dodo K, Kuboki E, Shimizu T, Imamura R, Magarisawa M, Takahashi M, Tokuhiro T, Yotsumoto S, Asano K, Nakao S, Terayama N, Suda T, Tanaka M, Sodeoka M.. (2019) Development of a Water-Soluble Indolylmaleimide Derivative IM-93 Showing Dual Inhibition of Ferroptosis and NETosis.. ACS Med Chem Lett, 10 (9): (1272-1278). [PMID:31531196] [10.1021/acsmedchemlett.9b00142]
21. Narayan S, Ramisetti S, Jaiswal AS, Law BK, Singh-Pillay A, Singh P, Amin S, Sharma AK.. (2019) ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.. Eur J Med Chem, 161 (456-467). [PMID:30384048] [10.1016/j.ejmech.2018.10.052]
22. Jang J, Son JB, To C, Bahcall M, Kim SY, Kang SY, Mushajiang M, Lee Y, Jänne PA, Choi HG, Gray NS.. (2017) Discovery of a potent dual ALK and EGFR T790M inhibitor.. Eur J Med Chem, 136 (497-510). [PMID:28528303] [10.1016/j.ejmech.2017.04.079]
23. Oukoloff K, Coquelle N, Bartolini M, Naldi M, Le Guevel R, Bach S, Josselin B, Ruchaud S, Catto M, Pisani L, Denora N, Iacobazzi RM, Silman I, Sussman JL, Buron F, Colletier JP, Jean L, Routier S, Renard PY.. (2019) Design, biological evaluation and X-ray crystallography of nanomolar multifunctional ligands targeting simultaneously acetylcholinesterase and glycogen synthase kinase-3.. Eur J Med Chem, 168 (58-77). [PMID:30798053] [10.1016/j.ejmech.2018.12.063]
24. Ensan D, Smil D, Zepeda-Velázquez CA, Panagopoulos D, Wong JF, Williams EP, Adamson R, Bullock AN, Kiyota T, Aman A, Roberts OG, Edwards AM, O'Meara JA, Isaac MB, Al-Awar R.. (2020) Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma.. J Med Chem, 63 (9): (4978-4996). [PMID:32369358] [10.1021/acs.jmedchem.0c00395]
25. Smil D, Wong JF, Williams EP, Adamson RJ, Howarth A, McLeod DA, Mamai A, Kim S, Wilson BJ, Kiyota T, Aman A, Owen J, Poda G, Horiuchi KY, Kuznetsova E, Ma H, Hamblin JN, Cramp S, Roberts OG, Edwards AM, Uehling D, Al-Awar R, Bullock AN, O'Meara JA, Isaac MB.. (2020) Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma.. J Med Chem, 63 (17): (10061-10085). [PMID:32787083] [10.1021/acs.jmedchem.0c01199]
26. Hamilton GL,Chen H,Deshmukh G,Eigenbrot C,Fong R,Johnson A,Kohli PB,Lupardus PJ,Liederer BM,Ramaswamy S,Wang H,Wang J,Xu Z,Zhu Y,Vucic D,Patel S. (2019) Potent and selective inhibitors of receptor-interacting protein kinase 1 that lack an aromatic back pocket group.. Bioorg Med Chem Lett, 29 (12.0): (1497-1501). [PMID:31000154] [10.1016/j.bmcl.2019.04.014]
27. Engers DW,Bollinger SR,Felts AS,Vadukoot AK,Williams CH,Blobaum AL,Lindsley CW,Hong CC,Hopkins CR. (2020) Discovery, synthesis and characterization of a series of 7-aryl-imidazo[1,2-a]pyridine-3-ylquinolines as activin-like kinase (ALK) inhibitors.. Bioorg Med Chem Lett, 30 (18): (127418-127418). [PMID:32750526] [10.1016/j.bmcl.2020.127418]
28. ten Dijke, P P and 8 more authors.. (1994) Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4.. The Journal of biological chemistry, (24): [PMID:8006002]
29. ten Dijke, P P and 7 more authors.. (1993) Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity.. Oncogene, [PMID:8397373]
30. Kirsch, T T, Nickel, J J and Sebald, W W.. (2000) Isolation of recombinant BMP receptor IA ectodomain and its 2:1 complex with BMP-2.. FEBS letters, (25): [PMID:10692589]
31. Gilboa, L L and 5 more authors.. (2000) Bone morphogenetic protein receptor complexes on the surface of live cells: a new oligomerization mode for serine/threonine kinase receptors.. Molecular biology of the cell, [PMID:10712517]
32. Kirsch, T T, Nickel, J J and Sebald, W W.. (2000) BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II.. The EMBO journal, (3): [PMID:10880444]
33. Kirsch, T T, Sebald, W W and Dreyer, M K MK.. (2000) Crystal structure of the BMP-2-BRIA ectodomain complex.. Nature structural biology, [PMID:10881198]
34. Nickel, J J, Dreyer, M K MK, Kirsch, T T and Sebald, W W.. (2001) The crystal structure of the BMP-2:BMPR-IA complex and the generation of BMP-2 antagonists.. The Journal of bone and joint surgery. American volume, [PMID:11263668]
35. Howe, J R JR and 8 more authors.. (2001) Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis.. Nature genetics, [PMID:11381269]
36. Zhou, X P XP and 28 more authors.. (2001) Germline mutations in BMPR1A/ALK3 cause a subset of cases of juvenile polyposis syndrome and of Cowden and Bannayan-Riley-Ruvalcaba syndromes.. American journal of human genetics, [PMID:11536076]
37. Friedl, Waltraut W and 13 more authors.. (2002) Juvenile polyposis: massive gastric polyposis is more common in MADH4 mutation carriers than in BMPR1A mutation carriers.. Human genetics, [PMID:12136244]
38. Sayed, M G MG and 11 more authors.. (2002) Germline SMAD4 or BMPR1A mutations and phenotype of juvenile polyposis.. Annals of surgical oncology, [PMID:12417513]
39. Kim, I-J IJ and 9 more authors.. (2003) Identification of a novel BMPR1A germline mutation in a Korean juvenile polyposis patient without SMAD4 mutation.. Clinical genetics, [PMID:12630959]
40. Keller, Sascha S, Nickel, Joachim J, Zhang, Jin-Li JL, Sebald, Walter W and Mueller, Thomas D TD.. (2004) Molecular recognition of BMP-2 and BMP receptor IA.. Nature structural & molecular biology, [PMID:15064755]
41. Cao, X X and 5 more authors.. (2006) Mapping of hereditary mixed polyposis syndrome (HMPS) to chromosome 10q23 by genomewide high-density single nucleotide polymorphism (SNP) scan and identification of BMPR1A loss of function.. Journal of medical genetics, [PMID:16525031]
42. Delnatte, Capucine C and 14 more authors.. (2006) Contiguous gene deletion within chromosome arm 10q is associated with juvenile polyposis of infancy, reflecting cooperation between the BMPR1A and PTEN tumor-suppressor genes.. American journal of human genetics, [PMID:16685657]
43. Klages, Jochen J and 6 more authors.. (2008) The solution structure of BMPR-IA reveals a local disorder-to-order transition upon BMP-2 binding.. Biochemistry, (18): [PMID:18937504]
44. Mahlawat, Pardeep P, Ilangovan, Udayar U, Biswas, Tanuka T, Sun, Lu-Zhe LZ and Hinck, Andrew P AP.. (2012) Structure of the Alk1 extracellular domain and characterization of its bone morphogenetic protein (BMP) binding properties.. Biochemistry, (14): [PMID:22799562]
45. Degenkolbe, Elisa E and 13 more authors.. (2013) A GDF5 point mutation strikes twice--causing BDA1 and SYNS2.. PLoS genetics, [PMID:24098149]
46. Hansen, Maren F MF and 8 more authors.. (2015) A novel POLE mutation associated with cancers of colon, pancreas, ovaries and small intestine.. Familial cancer, [PMID:25860647]
47. May-Dracka TL,Arduini R,Bertolotti-Ciarlet A,Bhisetti G,Brickelmaier M,Cahir-McFarland E,Enyedy I,Fontenot JD,Hesson T,Little K,Lyssikatos J,Marcotte D,McKee T,Murugan P,Patterson T,Peng H,Rushe M,Silvian L,Spilker K,Wu P,Xin Z,Burkly LC. (2018) Investigating small molecules to inhibit germinal center kinase-like kinase (GLK/MAP4K3) upstream of PKCθ phosphorylation: Potential therapy to modulate T cell dependent immunity.. Bioorg Med Chem Lett, 28 (10): (1964-1971). [PMID:29636220] [10.1016/j.bmcl.2018.03.032]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度